U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502807) titled 'Effect of Neurofast(R) Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults' on March 20.
Brief Summary: This study aims to evaluate anxiety and cardiovascular outcomes in individuals with the psycho-cardio phenotype, characterized by clinically relevant anxiety symptoms with or without established cardiovascular disease (CVD). The study will be conducted as a prospective, real-world interventional study over 12 weeks.
Participants will be allocated to either a group receiving Neurofast(R) supplementation (2 tablets per day) or a control group receiving no additional treatment. Psychological ...